Federated Hermes Inc. Reduces Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Federated Hermes Inc. lessened its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 35.5% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 380,873 shares of the company’s stock after selling 209,700 shares during the quarter. Federated Hermes Inc.’s holdings in Takeda Pharmaceutical were worth $4,928,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Capital Research Global Investors lifted its position in Takeda Pharmaceutical by 3.6% in the fourth quarter. Capital Research Global Investors now owns 14,297,805 shares of the company’s stock valued at $204,030,000 after acquiring an additional 503,446 shares during the last quarter. Mondrian Investment Partners LTD increased its position in shares of Takeda Pharmaceutical by 47.9% during the first quarter. Mondrian Investment Partners LTD now owns 12,079,962 shares of the company’s stock worth $169,119,000 after purchasing an additional 3,912,569 shares in the last quarter. Van ECK Associates Corp lifted its holdings in shares of Takeda Pharmaceutical by 21.1% in the 2nd quarter. Van ECK Associates Corp now owns 2,040,829 shares of the company’s stock valued at $26,408,000 after purchasing an additional 356,069 shares during the last quarter. OLD Mission Capital LLC boosted its position in shares of Takeda Pharmaceutical by 1,440.9% in the 4th quarter. OLD Mission Capital LLC now owns 1,041,526 shares of the company’s stock valued at $14,863,000 after purchasing an additional 973,935 shares during the period. Finally, Wells Fargo & Company MN grew its stake in Takeda Pharmaceutical by 1.7% during the 4th quarter. Wells Fargo & Company MN now owns 774,552 shares of the company’s stock worth $11,053,000 after buying an additional 12,756 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $14.82 on Thursday. The company has a current ratio of 1.26, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The stock has a market cap of $47.16 billion, a P/E ratio of 26.95, a P/E/G ratio of 0.27 and a beta of 0.54. The stock has a 50 day moving average of $14.27 and a two-hundred day moving average of $13.75. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $16.39.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.37 by $0.19. Takeda Pharmaceutical had a net margin of 6.02% and a return on equity of 10.11%. The firm had revenue of $7.75 billion during the quarter. On average, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.63 earnings per share for the current year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.